Boost for GSK as new bone marrow cancer drug drastically cuts risk of death in patients A cancer drug developed by GSK drastically cuts the risk of death in patients, trials have shown.
The pharma giant’s Blenrep treatment was shown in a recent study to have reduced the risk of death by 42 per cent in those suffering from multiple myeloma, a type of bone marrow cancer.
The results are a boost for GSK and boss Emma Walmsley (pictured), who has been trying to improve the pipeline of new drugs and vaccines.
Trial success: GSK boss Emma Walmsley (pictured), who has been trying to improve the pipeline of new drugs and vaccines.
While the disease is still incurable, the data showed patients taking Blenrep would survive nearly three years longer than those using existing treatments.
